Guanabenz-related amidinohydrazones: potent non-azole inhibitors of aldosterone biosynthesis
摘要:
A new series of potent, guanabenz-derived, non-steroidal aldosterone biosynthesis inhibitors are presented. Salient features of the structure-activity relationship indicate the requirement of a hydrophobic core, presence of a hydrophilic (or basic) peripheral appendage, and, in some cases, profound dependence on hydrazone stereochemistry. The most potent compound of the series, 29, was 2 orders of magnitude more potent than guanabenz as an aldosterone biosynthesis inhibitor.
A novel anti-tumour strategy by optimising a promising molecule targeting the TLR2/4 pathway simultaneously, which inhibits proliferation of multiple cancer cells.
通过同时优化一个有前景的分子靶向TLR2/4通路,这种新型的抗肿瘤策略可以抑制多种癌细胞的增殖。
Analysis of the binding sites of vitamin D 1α-hydroxylase (CYP27B1) and vitamin D 24-hydroxylase (CYP24A1) for the design of selective CYP24A1 inhibitors: Homology modelling, molecular dynamics simulations and identification of key binding requirements
作者:Ismail M. Taban、Jinge Zhu、Hector F. DeLuca、Claire Simons
DOI:10.1016/j.bmc.2017.08.036
日期:2017.10
with the conserved sequence (A/G) GX (E/D) (T/S), which assumes an essential role in the binding of an oxygen molecule for catalysis. Additional docking experiments with selective hCYP27B1 or hCYP24A1 inhibitors using both the hCYP27B1 model and a triple mutant hCYP24A1 model provided further support for the importance of H-bonding interactions with the three identified active site amino acids. To confirm
使用MOE建立了人CYP27B1的同源性模型,并通过hCYP27B1同源性模型和hCYP27B1-SDZ-88357复合物的分子动力学模拟对其进行了进一步优化。hCYP27B1-SDZ-88357复合物的对接结果表明,氨基酸Arg107,Asn387和Asp320在结合相互作用中具有重要作用,其中重要的酸-醇对的Asp320部分位于I-螺旋中,具有保守的序列(A / G )GX(E / D)(T / S),在催化氧分子的结合中起着至关重要的作用。使用hCYP27B1模型和三突变体hCYP24A1模型与选择性hCYP27B1或hCYP24A1抑制剂进行的其他对接实验,为与三个已鉴定的活性位点氨基酸进行H键相互作用的重要性提供了进一步的支持。为了确认Arg107的作用,根据与hCYP27B1模型的对接实验确定,设计的hCYP27B1化合物活性位点中的Asn387和Asp320会形成H键相互作用
[EN] 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] 6-ARYL PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES, COMPOSITIONS ET PROCEDES D'UTILISATION DE CES COMPOSES
申请人:SANOFI WINTHROP, INC.
公开号:WO1996028448A1
公开(公告)日:1996-09-19
(EN) 6-Aryl pyrazolo[3,4-d]pyrimidin-4-one derivatives, pharmaceutical compositions containing them and methods for effecting c-GMP-phosphodiesterase inhibition and for treating heart failure and/or hypertension.(FR) Cette invention concerne des dérivés 6-aryl pyrazolo[3,4-d]pyrimidin-4-one, des compositions pharmaceutiques contenant ces dérivés ainsi que des procédés permettant d'inhiber la c-GMP-phosphodiestérase et de traiter l'insuffisance cardiaque et/ou l'hypertension.